Advances in targeted therapies VII F C Breedveld, J R Kalden, and J S Smolen Ann Rheum Dis 2005; 64 (Supplement 4 ): iv1. doi:10.1136/ard.2005.044339 [Extract] [Full text] [PDF] [Request Permissions]
	Updated consensus statement on biological agents, specifically tumour necrosis factor (TNF) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, and P J Mease Ann Rheum Dis 2005; 64 (Supplement 4 ): iv2-iv14. doi:10.1136/ard.2005.044941 [Extract] [Full text] [Erratum] [PDF] [Request Permissions]
	Stimulation of autoimmunity by toll-like receptor ligands A Limmer, R Ganss, N Garbi, B Arnold, and G J Hämmerling Ann Rheum Dis 2005; 64 (Supplement 4 ): iv15-iv17. doi:10.1136/ard.2005.042556 [Extract] [Full text] [PDF] [Request Permissions]
	Biological drug use: US perspectives on indications and monitoring J J Cush Ann Rheum Dis 2005; 64 (Supplement 4 ): iv18-iv23. doi:10.1136/ard.2005.042549 [Abstract] [Full text] [PDF] [Request Permissions]
	Immunological control of tuberculosis: role of tumour necrosis factor and more S Stenger Ann Rheum Dis 2005; 64 (Supplement 4 ): iv24-iv28. doi:10.1136/ard.2005.042531 [Abstract] [Full text] [PDF] [Request Permissions]
	Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor K L Winthrop Ann Rheum Dis 2005; 64 (Supplement 4 ): iv29-iv30. doi:10.1136/ard.2005.042390 [Extract] [Full text] [PDF] [Request Permissions]
	Current state of tumour necrosis factor blockade in Wegener’s granulomatosis C Mukhtyar and R Luqmani Ann Rheum Dis 2005; 64 (Supplement 4 ): iv31-iv36. doi:10.1136/ard.2005.042416 [Abstract] [Full text] [PDF] [Request Permissions]
	The CORRONA database J Kremer Ann Rheum Dis 2005; 64 (Supplement 4 ): iv37-iv41. doi:10.1136/ard.2005.043497 [Extract] [Full text] [PDF] [Request Permissions]
	The British Society for Rheumatology Biologics Register K Watson, D Symmons, I Griffiths, and A Silman Ann Rheum Dis 2005; 64 (Supplement 4 ): iv42-iv43. doi:10.1136/ard.2005.042499 [Abstract] [Full text] [PDF] [Request Permissions]
	What are the roles of metalloproteinases in cartilage and bone damage? G Murphy and M H Lee Ann Rheum Dis 2005; 64 (Supplement 4 ): iv44-iv47. doi:10.1136/ard.2005.042465 [Abstract] [Full text] [PDF] [Request Permissions]
	Presentation and analysis of radiographic data in clinical trials and observational studies R Landewé and D van der Heijde Ann Rheum Dis 2005; 64 (Supplement 4 ): iv48-iv51. doi:10.1136/ard.2005.042572 [Abstract] [Full text] [PDF] [Request Permissions]
	Are fibroblasts involved in joint destruction? T Pap, I Meinecke, U Müller-Ladner, and S Gay Ann Rheum Dis 2005; 64 (Supplement 4 ): iv52-iv54. doi:10.1136/ard.2005.042424 [Extract] [Full text] [PDF] [Request Permissions]
	Update on rituximab R Eisenberg Ann Rheum Dis 2005; 64 (Supplement 4 ): iv55-iv57. doi:10.1136/ard.2005.042648 [Extract] [Full text] [PDF] [Request Permissions]
	Alefacept for psoriasis and psoriatic arthritis A B Gottlieb Ann Rheum Dis 2005; 64 (Supplement 4 ): iv58-iv60. doi:10.1136/ard.2005.042655 [Abstract] [Full text] [PDF] [Request Permissions]
	How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? J Sieper and M Rudwaleit Ann Rheum Dis 2005; 64 (Supplement 4 ): iv61-iv64. doi:10.1136/ard.2005.042432 [Abstract] [Full text] [PDF] [Request Permissions]
	Health economics: implications for novel antirheumatic therapies A Kavanaugh Ann Rheum Dis 2005; 64 (Supplement 4 ): iv65-iv69. doi:10.1136/ard.2005.042440 [Abstract] [Full text] [PDF] [Request Permissions]
	What does tumour necrosis factor excess do to the immune system long term? J Clark, P Vagenas, M Panesar, and A P Cope Ann Rheum Dis 2005; 64 (Supplement 4 ): iv70-iv76. doi:10.1136/ard.2005.042523 [Abstract] [Full text] [PDF] [Request Permissions]
	How does B cell depletion therapy work, and how can it be improved? E A Clark and J A Ledbetter Ann Rheum Dis 2005; 64 (Supplement 4 ): iv77-iv80. doi:10.1136/ard.2005.042507 [Abstract] [Full text] [PDF] [Request Permissions]
	IKKß as a target for treatment of inflammation induced bone loss M G Ruocco and M Karin Ann Rheum Dis 2005; 64 (Supplement 4 ): iv81-iv85. doi:10.1136/ard.2005.042721 [Abstract] [Full text] [PDF] [Request Permissions]
	Dendritic cells: potential triggers of autoimmunity and targets for therapy J A Hardin Ann Rheum Dis 2005; 64 (Supplement 4 ): iv86-iv90. doi:10.1136/ard.2005.044560 [Extract] [Full text] [PDF] [Request Permissions]
	Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases N Beyersdorf, T Hanke, T Kerkau, and T Hünig Ann Rheum Dis 2005; 64 (Supplement 4 ): iv91-iv95. doi:10.1136/ard.2005.042564 [Abstract] [Full text] [PDF] [Request Permissions]
	The coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders J M Ilarregui, G A Bianco, M A Toscano, and G A Rabinovich Ann Rheum Dis 2005; 64 (Supplement 4 ): iv96-iv103. doi:10.1136/ard.2005.044347 [Abstract] [Full text] [PDF] [Request Permissions]
	Toll-like receptor 2 signalling and inflammation F Y Liew, M Patel, and D Xu Ann Rheum Dis 2005; 64 (Supplement 4 ): iv104-iv105. doi:10.1136/ard.2005.042515 [Extract] [Full text] [PDF] [Request Permissions]
	The 2005 International Symposium on Advances in Targeted Therapies: What have we learned in the 2000s and where are we going? R N Maini Ann Rheum Dis 2005; 64 (Supplement 4 ): iv106-iv108. doi:10.1136/ard.2005.042408 [Abstract] [Full text] [PDF] [Request Permissions]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.